1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Merck KGaA

Merck KGaA

MKKGY
Merck KGaAUS flagOther OTC
32.12
USD
-0.97
- -
69.83BMarket Cap
Merck KGaA
MKKGY
(Other OTC)

Recent

price

32.12

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.27
4.73
5.15
5.11
5.22
5.9
6.92
6.68
6.82
7.43
8.07
9.06
10.23
9.66
9.73
9.71
7.21
Revenue per Share
0.3
0.28
0.26
0.55
0.53
0.51
0.75
1.2
1.55
0.61
0.91
1.41
1.53
1.3
1.28
1.2
0.86
Basic EPS, GAAP
0.59
0.38
0.92
0.79
0.96
0.69
0.77
0.64
0.55
0.84
0.88
1.47
1.13
0.81
1.1
0.91
0.96
Free Cash Flow per Basic Share
0.04
0.04
0.2
0.19
0.23
0.26
0.27
0.29
0.07
0.07
0.08
0.08
0.11
0.13
0.13
0.13
0.01
Dividend per Share
23.77
24.03
23.83
25.35
27.01
29.41
32.18
32.21
39.56
41.03
38.98
49.08
59.63
61.36
68.8
65.76
- -
Book Value per Share
-4.94
-3.03
-1.34
2.65
0.8
-29.06
-25.31
-18.17
-8.74
-19.54
-15.33
-7.54
0.47
5.25
10.25
6.89
- -
Tangible Book Value per Share
2,174
2,174
2,171
2,170
2,175
2,178
2,172
2,174
2,174
2,174
2,174
2,174
2,174
2,174
2,174
2,174
2,177
Basic Weighted Avg Shares
9,291
10,276
11,173
11,095
11,363
12,845
15,024
14,517
14,836
16,152
17,534
19,687
22,232
20,993
21,156
21,102
15,701
Sales/Revenue/Turnover
11.9
11.98
16.93
18.83
15.39
16.88
15.45
15.23
12.36
14.26
16.03
21.38
21.37
17.02
18.95
17.33
17.21
Operating Margin (%)
1,258
1,597
1,397
1,458
1,361
1,511
1,934
1,758
1,812
1,944
1,938
1,767
2,030
1,880
2,134
2,298
1,865
Depreciation Expense
642
606
567
1,202
1,157
1,115
1,629
2,605
3,374
1,320
1,987
3,055
3,326
2,824
2,777
2,608
1,880
Net Income, GAAP
25.5
26.32
18.34
12.93
25.19
24.75
24.19
- -
25.19
25.36
24.22
21.89
22.11
18.66
21.24
20.95
20.99
Effective Tax Rate (%)
6.9
5.9
5.07
10.84
10.18
8.68
10.84
17.94
22.74
8.17
11.33
15.52
14.96
13.45
13.13
12.36
11.97
Profit Margin (%)
2,306
2,037
2,064
3,486
3,879
-2,040
-1,419
-1,180
719
-2,839
49
550
2,687
3,694
2,155
4,188
- -
Working Capital
5,127
3,989
3,362
3,258
3,444
9,513
8,705
7,946
6,681
8,587
9,745
8,270
9,200
9,239
6,998
10,731
- -
LT Debt
10,377
10,494
10,415
11,069
11,801
12,855
14,050
14,066
17,233
17,914
17,017
21,416
26,005
26,755
29,989
28,660
- -
Total Equity
6.33
5.61
9.88
11.99
7.85
7.17
6.47
- -
5.2
5.74
6.73
10.19
10.29
7.62
7.88
6.86
10.86
Return on Invested Capital (%)
4.98
5.24
5.22
9.52
8.21
6.27
7.12
- -
14.12
5.85
7.57
10.64
10.19
8.42
7.8
7.19
11.31
Return on Capital (%)
6.48
5.84
5.45
11.25
10.17
9.09
12.17
18.61
21.63
7.53
11.42
15.96
14.07
10.74
9.81
8.92
13.31
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,221
1,236
- -
LT Borrowings
10,206
- -
- -
LT Finance Leases
525
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
435
435
435
Market Capitalization
10,616
9,487
12,760

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
13,230
14,162
- -
Cash, Cash Equivalents & STI
2,925
3,774
- -
Accounts Receivable, Net
3,947
4,318
- -
Inventories
4,562
4,782
- -
Total Current Liabilities
9,042
9,349
- -
Payables & Accruals
- -
- -
- -
ST Debt
1,221
1,236
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.87%
11.56%
-4.43%
Free Cash Flow
7.19%
6.82%
-17.82%
Net Income, GAAP
16.5%
7.96%
-6.09%
Sales/Revenue/Turnover
5.34%
4.03%
-0.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,120
5,352
5,266
5,418
21,156
2025
5,280
5,255
5,318
5,249
21,102
2026
5,134
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.32
0.28
0.37
- -
1.28
2025
0.34
0.3
0.41
- -
1.2
2026
0.3
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.13
- -
- -
0.13
2025
0.02
0.13
- -
- -
0.13
2026
0.01
- -
- -
- -
- -
Similar Companies
Tasly Pharmaceutical Group Co., Ltd (600535.SS)
Delta 9 Cannabis Inc. (DLTNF)
Kunming Longjin Pharmaceutical Co., Ltd. (002750.SZ)
Biotest AG (BIO1.F)
Hempstract, Inc. (HPST)
Lavipharm S.A. (LAVI.AT)
Business
Merck KGaA, Darmstadt, Germany operates as a global science and technology company with core business sectors in Healthcare, Life Science, and Electronics. The company manufactures and markets pharmaceutical and biological prescription drugs targeting oncology, neurology, immunology, fertility, cardiovascular, metabolic, and endocrinological disorders. Its key pharmaceutical products include cancer therapies such as Erbitux (cetuximab), Bavencio, and Mavenclad for multiple sclerosis. The company also develops specialty drugs addressing growth disorders and infertility. In life sciences, Merck offers process solutions, life science services, science and lab solutions, and semiconductor materials, supporting research, manufacturing, and technology innovation. The Electronics sector focuses on semiconductor solutions benefiting from trends like AI and IoT. Headquartered in Darmstadt, Germany, Merck was founded in 1668 and operates globally. Recent major developments include the acquisition of US biopharma SpringWorks Therapeutics in 2025, enhancing Merck’s presence in rare tumors and expanding its U.S. footprint. The company completed acquisition of CN201, a bispecific antibody for B-cell malignancies and autoimmune diseases, expanding its clinical pipeline. Merck also signed a strategic partnership with Caris Life Sciences to discover novel therapeutic targets for antibody-drug conjugates in oncology. In 2025, Merck deepened its digital transformation collaboration with Siemens, focusing on AI and automation in drug discovery and manufacturing. Additionally, Merck plans to acquire ophthalmology-focused EyeBio, advancing its pipeline in retinal diseases. The company continues to invest over €1 billion in mRNA technology manufacturing capabilities, opening new GMP-grade sites in Germany. These strategies underscore Merck’s focus on innovation, external growth, and digital integration across its business sectors.

Company News

Company News APIChatGPT

  • wsj.com

    Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

  • defenseworld.net

    Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head Contrast

  • defenseworld.net

    Merck KGaA (OTCMKTS:MKKGY) Shares Shorted: Short Interest Up 95.4% in September

  • defenseworld.net

    Merck KGaA (OTCMKTS:MKKGY) Receives Consensus Rating of “Hold” from Brokerages

  • seekingalpha.com

    Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript

  • zacks.com

    Merck KGaA (MKKGY) Misses Q2 Earnings Estimates

  • businesswire.com

    Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development

  • zacks.com

    Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade

  • zacks.com

    Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

  • zacks.com

    Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?

  • benzinga.com

    Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal

  • barrons.com

    Germany's Merck Is Buying Bio-Techne for $11.3 Billion

  • reuters.com

    Germany's Merck to buy Bio-Techne for $73 per share

  • wsj.com

    Germany's Merck to Buy Bio-Techne for $11 Billion

  • zacks.com

    Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

  • zacks.com

    Should Value Investors Buy Merck KGaA (MKKGY) Stock?

  • seekingalpha.com

    Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript

  • marketbeat.com

    Merck KGaA Q1 Earnings Call Highlights

  • zacks.com

    Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates

  • businesswire.com

    Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations